Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Preservative-Free Tafluprost in Pediatric Glaucoma
NCT02102750Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tafluprost in pediatric glaucoma and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Plasma concentration of tafluprost acid at 8 days. Started Jun 2014; status: completed.
02
Drugs
tafluprost
03
Conditions
pediatric glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02102750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102750.